

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/591,164	08/30/2006	Naoki Nagahara	2006_1328A	6045		
513 WENDEROTE	7590 11/07/2007 H, LIND & PONACK, L	EXAMINER				
2033 K STREI		DICKINSO	DICKINSON, PAUL W			
SUITE 800 WASHINGTO	N, DC 20006-1021	ART UNIT	PAPER NUMBER			
	,		4173			
			MAIL DATE	DELIVERY MODE		
			11/07/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)				
		10/591,164	NAGAHARA ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Paul W. Dickinson	4173				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with th	e correspondence address				
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (a) In no event, however, may a reply be defined and will expire SIX (6) MONTHS for cause the application to become ABANDO	ON. e timely filed from the mailing date of this communication. DNED (35 U.S.C. § 133).				
Status							
1)[Responsive to communication(s) filed on						
′=	•	action is non-final.					
3)	Since this application is in condition for allowar		prosecution as to the merits is				
٠,۵	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims		·				
4) 🖂	Claim(s) <u>1-24</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdraw	•					
5)[Claim(s) is/are allowed.						
6)[Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)🖾	Claim(s) 1-24 are subject to restriction and/or e	election requirement.					
Applicati	on Papers						
9)	The specification is objected to by the Examine	r.					
•—	The drawing(s) filed on is/are: a) acce		e Examiner.				
	Applicant may not request that any objection to the	drawing(s) be held in abeyance.	See 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is	objected to. See 37 CFR 1.121(d).				
11) 🔲	The oath or declaration is objected to by the Ex	aminer. Note the attached Offi	ce Action or form PTO-152.				
Priority u	ınder 35 U.S.C. § 119						
	Acknowledgment is made of a claim for foreign All b) Some * c) None of:		(a)-(d) or (f).				
	1. Certified copies of the priority documents		War Ma				
	2. Certified copies of the priority documents	• • • • • • • • • • • • • • • • • • • •					
	 Copies of the certified copies of the prior application from the International Bureau 	•	ived in this National Stage				
* 5	See the attached detailed Office action for a list of		ived				
	see the attached detailed embe detail for a list of	or the certifical copies flot rese.	vou.				
Attachmen	t(s)						
1) Notic	e of References Cited (PTO-892)	4) Interview Summa					
	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application 6) Other:							

DETAILED ACTION

Election

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

First Election Requirement of Six

Applicant is required to elect a single species of medicine unstable to moisture (see Claims 1, 7-13). If Applicant elects formula (I') of claim 8, Applicant is further required to elect a specific group for each of R⁰, R¹, R², R³, Y, and C'. The disclosed medicines have different molecular structures and exhibit different chemical and pharmacological behaviors.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 1-6, 14-24 are generic to the above.

Second Election Requirement of Six

Applicant is required to elect whether or not the main component of the capsule is a gelatin containing polyethylene glycol (see Claims 3 and 6). A capsule having a

main component of polyethylene glycol will exhibit different chemical and pharmacological behaviors than one without.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 1-2, 7-24 are generic to the above.

Third Election Requirement of Six

Applicant is required to elect whether or not the main component of the capsule is a water-soluble polysaccharide (see Claim 4). A capsule having a main component of a water-soluble polysaccharide will exhibit different chemical and pharmacological behaviors than one without.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 1-2, 7-24 are generic to the above.

Fourth Election Requirement of Six

Applicant is required to elect whether or not the main component of the capsule is pullulan (see Claims 5-6). A capsule having a main component of pullalan will exhibit different chemical and pharmacological behaviors than one without.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 1-2, 7-24 are generic to the above.

Fifth Election Requirement of Six

Applicant is required to elect whether or not the capsule preparation comprises at least two solid preparations selected from fine granules, granules and tablets in combination (see Claim 16). A capsule with at least two solid preparations will exhibit different pharmacological behaviors than one with only one solid preparation.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 1-15 are generic to the above.

Art Unit: 4173

Sixth Election Requirement of Six

Applicant is required to elect whether or not the capsule preparation comprises a coating (see Claims 18-24). A capsule with a coating will exhibit different pharmacological behaviors than one without a coating.

The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 1-17 are generic to the above.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of

Art Unit: 4173

record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Paul W. Dickinson whose telephone number is 571-270-3499. The examiner can normally be reached on Mon-Thur 7:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/591,164

Art Unit: 4173

Page 7

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Paul W. Dickinson Examiner Art Unit 4173

October 29, 2007

ARDIN H. MARSCHEL

SUPERVISORY PATENT EXAMINER

#####	####	#		##	#				
# #	# #			#					
# #	# #	###	### #	# ####.	###	## ##	#####	####	## ##
# #	# #	#	# ##	# #	#	## #	# #	# #	## #
####	# #	#	#	###	#	# #	####	# #	# #
#	# #	#	#	# #	#	# #	#	# #	# #
#	# #	· #	# #	# #	#	# #	# #	# #	# #
###	####	#####	####	## ###	#####	### ###	#####	####	### ###

Job : 141

Date: 10/29/2007 Time: 2:34:41 PM